Treatment for human papillomavirus-associated cancers

With the development of CMD-004 we aim to generate immune cells that recognize and destroy cancer cells infected with human papillomavirus (HPV).

HPV belongs to the family of papilloma viruses and represents a virus that will infect approximately 80% of people at some point in their lives.

While most HPV infections are benign, some infections persist and can develop into cancerous lesions. In some cases, these lesions can progress into invasive cancer, particularly in the cervix and the oropharyngeal and anogenital regions.

Currently, no cure is available for HPV infection, although HPV vaccines have been introduced as a protection against cervical cancer. However, as vaccination is not carried out universally and boys are generally not vaccinated, HPV-associated cancers remain a major health concern.

Immune cell therapy for HPV-associated cancers

We are developing HPV-specific T cells (CMD-004) to target these cancers.